PubMed · 9309162
[Phospholipase C inhibitor].
Abstract
N-Myristoylated PCI peptide, myr-PCI, originally developed based on the PCI sequence of PLC- gamma 2, inhibited activity of purified PLC isoforms in vitro, and external stimuli-dependent IP3 formation in Swiss 3T3 cells. When myr-PCI was added to KMS-8 cells, derived from familial adenomatous polyposis patients, it also suppressed the serum-dependent IP3 formation, DNA synthesis, and cell growth. In order to develop PCI peptides with strong anti-PLC activity, we synthesized the peptides whose N- and/or C-termini were acylated by a variety of compounds, and examined their anti-PLC and anti-proliferative activities. Results would be quite helpful to determine the minimal structure required for PLC inhibition in vivo.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Y Homma, M Homma. 1997. [Phospholipase C inhibitor].. https://pubmed.ncbi.nlm.nih.gov/9309162/
Cite the original work for its findings. Save a collection to share your selection of sources.